Prostate Cancer Diagnostics and Therapy Market - Growth, Trends, and Forecast (2020 - 2025)

The Prostate Cancer Diagnostics and Therapy Market is segmented by Type, Modality, and Geography.

  • ABOUT THIS REPORT
    • Market Snapshot
    • Market Overview
    • Scope of the Report
    • Key Market Trends
    • Competitive Landscape
    • Major Players
  • TABLE OF CONTENTS

Market Snapshot

Study Period:

2016-2024

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

Major Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

The prostate cancer diagnostics and therapy market is expected to register a CAGR of nearly 6.1% during the forecast period, 2019-2024. 

  • The major factor driving the growth of the market studied is aging population and high prevalence rate of prostate cancer. Prostate cancer is the second most common type of cancer in male population. About 80% of men who reach 80 years of age are diagnosed with it.
  • As per the estimates provided by the American Cancer Society, in 2018, the United States is expected to witness over 164,690 new cases of prostate cancer, with over 29,430 related deaths. Nearly 60% of the total prostate cancer cases diagnosed are among men aged 65 years or older. One in every nine men is expected to be diagnosed with prostate cancer during his lifetime.
  • In addition, according to the United States Census Bureau’s Statistics, the total number of people aged 65 and older exceeds 50 million as of 2017, and the number of elderly is projected to increase by almost 18 million during 2020-2030. The number of people aged 85 and older is expected to triple from an estimated 6 million of today to nearly 20 million, by 2060. The risk of developing prostate cancer increases significantly with age, and rise in geriatric population is one of the leading factors that contribute to the expansion of the market.

Scope of the Report

The prostate gland is located in the pelvis, below the bladder and in front of the rectum. Prostate cancer begins when normal cells in the prostate begin to multiply uncontrollably.  The scope of the study is limited to revenue generated by various diagnostic and therapeutic products used in the management of benign prostatic hyperplasia, prostatic adenocarcinoma, and small cell carcinoma, among other types of prostate cancer.

By Type
Benign Prostatic Hyperplasia
Prostatic Adenocarcinoma
Small Cell Carcinoma
Other Types
By Modality
Diagnosis
Tissue Biopsy
Transrectal Ultrasound
Clinical Laboratory Examination
Prostate-specific Antigen Testing
Urine Testing
Diagnostic Imaging
Treatment
Surgery
Radiation Therapy
Therapeutics
Hormone Therapy
Chemotherapy
Other Treatments
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Prostate-specific Antigen (PSA) Testing Segment is Expected to Grow at Rapid Pace.

Prostate-specific Antigen (PSA) is a protein produced by prostate cells. Therefore, the PSA test is performed to diagnose prostate cancer (PCa) in men and for follow-up post treatment to check if the cancer relapses. PSA testing is an important tool for detecting prostate cancer, which measures the level of PSA in a man’s blood. Medicare and several private insurers provide coverage for an annual PSA test for all Medicare-eligible men aged 50 and older. The PSA testing is gaining popularity among clinicians and hospitals, owing to the increasing number of people being affected by prostate cancer. It has more market value in the countries with high prevalence rate (Western) and low prevalence rate (Asian), as PSA is used globally for the early detection/screening of prostate cancer.

PSA testing is anticipated to reduce the likelihood of death from prostate cancer. Refinements of the prostate-specific antigen (PSA) test have been developed to reduce the number of false positive results. Therefore, due to the rising prevalence of prostate cancer, the market is expected to witness high growth rate, over the forecast period.

To understand key trends, Download Sample Report

United States is Expected to Retain the Largest Market Share During the Period of Forecast.

Prostate cancer is considered as one of the most common cancers among American men, and more than 60% of all prostate cancers are diagnosed in men older than 65. According to the American Cancer Society’s, 2019, there are about 174,650 new cases of prostate cancer accounting for 31,620 deaths. Hence, it is considered to have an early diagnosis of the condition. In case of the treatment, the early stages of prostate cancer are treated by radiation therapy and for the late stages, where it has spread beyond the prostate gland, hormone therapy, chemotherapy, and or immunotherapy treatments, are recommended. In the case of benign prostatic hyperplasia (BPH), resectoscopy is the major treatment procedure. Zytiga and Xtandi are the major therapeutics that are used for treatment. Zytiga is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). With promising pipeline drugs, such as Apalutamide, the market of therapeutics is expected to increase.

To understand geography trends, Download Sample Report.

Competitive Landscape

Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as a major player lies primarily within specific product markets. Key players in the market include Abbott Laboratories, Astellas Inc., AstraZeneca, Bayer HealthCare AG, Cellanyx Diagnostics Inc, Dendreon Corporation, Ferring Pharmaceuticals, Ipsen Group, Sanofi-Aventis, Tolmar Inc, GE Healthcare,  Siemens Healthineers, and F. Hoffmann-La Roche AG, among others.

Major Players

  1. Ipsen SA
  2. Bayer AG
  3. Astellas Pharma Inc.
  4. AstraZeneca PLC
  5. Sanofi-Aventis

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Aging Population and High Prevalence Rate of Prostate Cancer

      2. 4.2.2 Innovation in Drugs and Developments in Genomics and Proteomics

      3. 4.2.3 Increasing Government Initiatives for Cancer Awareness

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Prostate Cancer Drugs

      2. 4.3.2 Low Success Rate of Clinical Trials

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type

      1. 5.1.1 Benign Prostatic Hyperplasia

      2. 5.1.2 Prostatic Adenocarcinoma

      3. 5.1.3 Small Cell Carcinoma

      4. 5.1.4 Other Types

    2. 5.2 By Modality

      1. 5.2.1 Diagnosis

        1. 5.2.1.1 Tissue Biopsy

        2. 5.2.1.2 Transrectal Ultrasound

        3. 5.2.1.3 Clinical Laboratory Examination

          1. 5.2.1.3.1 Prostate-specific Antigen Testing

          2. 5.2.1.3.2 Urine Testing

        4. 5.2.1.4 Diagnostic Imaging

      2. 5.2.2 Treatment

        1. 5.2.2.1 Surgery

        2. 5.2.2.2 Radiation Therapy

        3. 5.2.2.3 Therapeutics

          1. 5.2.2.3.1 Hormone Therapy

          2. 5.2.2.3.2 Chemotherapy

          3. 5.2.2.3.3 Other Treatments

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Ipsen SA

      2. 6.1.2 Bayer AG

      3. 6.1.3 Astellas Pharma Inc.

      4. 6.1.4 Abbvie Inc.

      5. 6.1.5 Dendreon Pharmaceuticals LLC

      6. 6.1.6 AstraZeneca PLC

      7. 6.1.7 Sanofi-Aventis

      8. 6.1.8 Tolmar Inc.

      9. 6.1.9 Koninklijke Philips NV

      10. 6.1.10 Hologic Inc.

      2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

Related Reports

    LINKS

    CONTACT

    Location Logo

    5th Floor, Brigade Towers,

    Financial District, Gachibowli,

    Hyderabad - 500032,

    India

    Phone Logo

    +1 617-765-2493

    Email Logo[email protected]

    JOIN US

    We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination.

    Interested? Please email us

    [email protected]

    © 2020. All Rights Reserved to Mordor Intelligence.